Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 iBio Advances Lead COVID Vax Program IBIO-202 | Contract Pharma

What are you searching for?

Sign in
Breaking News

iBio Advances Lead COVID Vax Program IBIO-202

Moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid (“N”) protein.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

iBio, Inc., a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, shared an update on its lead COVID-19 vaccine program, IBIO-202.
 
iBio recently received the U.S. FDA response to its pre-investigational new drug (IND) package for IBIO-202 and is moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid (“N”) protein and plans to file an IND application before the end of calendar 2022.
 
Commercially available first-generation vaccines target the frequently mutating spike (“S”) protein, resulting in waning periods of immunity and the spread of new variants. Meanwhile, evidence continues to emerge that “N-, not S-, reactive T cells appear to play a protective role” for SARS-CoV-2 and potentially other betacoronaviruses as well.
 
The company previously reported that it had completed extensive preclinical studies and identified an antigen-adjuvant pairing with a favorable Th1 skew. The cytokine response observed with this pairing indicated activation of a primary immune response, differentiation of mature T cells, and reactivation of memory T-cells.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics